Edwards Lifesciences (NYSE:EW) VP Sells 2,644 Shares

Key Points

• Edwards Lifesciences VP Annette Bruls sold 2,644 shares for approximately $237,907, reducing her ownership by 12.82% to 17,984 shares.
• Shares rose 0.3% to $90.19, while the company reported quarterly revenue of $1.74 billion and EPS of $0.78, beating analyst expectations; revenue increased 13.6% year over year.
• Wall Street maintains a “Moderate Buy” consensus, with 17 Buy and six Hold ratings and an average price target of $100.27.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Annette Bruls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company's stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Edwards Lifesciences Stock Up 0.3%

Edwards Lifesciences stock traded up $0.24 during midday trading on Friday, hitting $90.19. The stock had a trading volume of 2,043,685 shares, compared to its average volume of 4,699,688. The business has a fifty day moving average price of $89.48 and a 200 day moving average price of $84.99. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The stock has a market cap of $51.93 billion, a P/E ratio of 51.83, a P/E/G ratio of 2.38 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences's quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in the stock. Rehmann Capital Advisory Group grew its position in shares of Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after acquiring an additional 130 shares during the last quarter. McIlrath & Eck LLC lifted its position in Edwards Lifesciences by 14.6% in the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company's stock valued at $90,000 after purchasing an additional 135 shares during the last quarter. Quadrant Capital Group LLC lifted its position in Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock valued at $1,288,000 after purchasing an additional 136 shares during the last quarter. Stephens Inc. AR boosted its stake in Edwards Lifesciences by 5.4% during the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock valued at $239,000 after purchasing an additional 144 shares during the period. Finally, Composition Wealth LLC boosted its stake in Edwards Lifesciences by 1.6% during the 4th quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company's stock valued at $795,000 after purchasing an additional 147 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent research reports. Citigroup boosted their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, July 8th. UBS Group initiated coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price target on the stock. Truist Financial boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a research report on Thursday, July 16th. BTIG Research boosted their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Tuesday, June 30th. Finally, Mizuho increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source